Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 203.3% in January

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 31st total of 6,100 shares. Based on an average trading volume of 10,700 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.2% of the shares of the company are short sold.

Armata Pharmaceuticals Price Performance

Shares of ARMP traded up $0.01 on Thursday, reaching $2.05. The company’s stock had a trading volume of 3,615 shares, compared to its average volume of 10,464. The firm has a market capitalization of $74.17 million, a PE ratio of -1.25 and a beta of 0.85. Armata Pharmaceuticals has a twelve month low of $1.80 and a twelve month high of $4.48.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.